Esko WP

Vertex monopoly of the cystic fibrosis space signalled by another label expansion

On 28 April, the European Commission (EC) approved the label expansion for Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor + ivacaftor) for the treatment of cystic fibrosis (CF) in all patients aged 12 years and older who are heterozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation (F), regardless of the other mutation type, either gating (G) or residual function (RF) mutations.


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.